Developing first-in-class therapeutics that degrade extracellular proteins to address difficult-to-treat diseases

We are building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.

Latest News

Lysosome-targeting chimaeras for degradation of extracellular proteins

Read More

Versant Ventures Launches Lycia Therapeutics with $50 Million

Read More

Carolyn Bertozzi’s glycorevolution

Read More

Contact Us Join Lycia
681 Gateway Blvd., 3rd floor, South San Francisco, CA 94080
Top